About Gammadelta therapeutics
Gammadelta Therapeutics: Revolutionizing Cancer Treatment with Innovative Immunotherapies
Gammadelta Therapeutics is a pioneering biotechnology company that is dedicated to developing innovative immunotherapies for the treatment of cancer. The company was founded in 2017 as a spin-off from Takeda Pharmaceutical Company Limited, one of the world's leading research-based pharmaceutical companies.
Gammadelta Therapeutics is focused on harnessing the power of gamma delta (γδ) T cells, a unique subset of immune cells that have been shown to play a critical role in cancer immunity. These cells are capable of recognizing and killing cancer cells directly, without requiring prior exposure or activation by other immune cells.
The company's lead product candidate, GDT-BY01, is an allogeneic γδ T cell therapy that has demonstrated promising results in preclinical studies. The therapy involves collecting γδ T cells from healthy donors and expanding them ex vivo before infusing them into patients with solid tumors.
GDT-BY01 has several advantages over existing immunotherapies such as checkpoint inhibitors and CAR-T cell therapies. Unlike these therapies, which target specific antigens expressed on cancer cells, GDT-BY01 can recognize and kill a broad range of tumor types regardless of their antigen expression profile. Moreover, GDT-BY01 does not require genetic modification or personalized manufacturing for each patient.
In addition to GDT-BY01, Gammadelta Therapeutics has several other pipeline candidates in various stages of development. These include:
- GDT-CR02: A CAR-γδ T cell therapy targeting solid tumors expressing mesothelin.
- GDT-CR03: A bispecific antibody targeting both γδ T cells and tumor-associated antigens.
- GDT-CR04: An oncolytic virus engineered to selectively replicate in and destroy cancer cells while stimulating γδ T cell-mediated anti-tumor immunity.
Gammadelta Therapeutics has a world-class team of scientists and clinicians with extensive experience in immunology, oncology, and drug development. The company has also established collaborations with leading academic institutions and biotech companies to advance its research programs.
The potential of γδ T cell therapy in cancer treatment has attracted significant interest from the pharmaceutical industry and investors. Gammadelta Therapeutics has raised over $100 million in funding to date from top-tier venture capital firms such as Versant Ventures, F-Prime Capital, and Takeda Ventures.
In conclusion, Gammadelta Therapeutics is at the forefront of a new era in cancer treatment that promises to revolutionize the way we fight this devastating disease. With its innovative γδ T cell therapies and strong scientific expertise, the company is well-positioned to make a significant impact on patients' lives worldwide.